Introduction Aztreonam avibactam for Stenotrophomonas maltophilia is an emerging area of interest because this organism has intrinsic resistance mechanisms that limit the activity of many conventional β-lactam antibiotics. Stenotrophomonas maltophilia is a Gram-negative organism that can cause healthcare-associated infections, particularly in patients with significant underlying illness or prolonged healthcare exposure. One of the challenges in...Read More

Introduction Aztreonam avibactam for NDM-producing Enterobacterales has become an important area of interest in the management of antimicrobial-resistant Gram-negative infections. NDM, or New Delhi metallo-β-lactamase, is a metallo-β-lactamase (MBL) that can hydrolyze many β-lactam antibiotics, including carbapenems. However, aztreonam has a distinctive property: it is stable to hydrolysis by MBLs such as NDM. The challenge...Read More

The aztreonam avibactam mechanism of action is based on the complementary activity of two components: aztreonam, a monobactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Aztreonam targets bacterial cell-wall synthesis by binding primarily to penicillin-binding protein 3 (PBP3), while avibactam protects aztreonam from hydrolysis by several serine beta-lactamases. Importantly, avibactam does not directly inhibit metallo-beta-lactamases...Read More